Literature DB >> 30215116

Neurological symptoms in Hypophosphatasia.

J M Colazo1,2, J R Hu1, K M Dahir3, J H Simmons4.   

Abstract

Hypophosphatasia (HPP) typically manifests with fractures, tooth loss, and muscle pain. Although mental health diagnoses and neurological symptoms have not been previously well documented in HPP, they occur commonly. The recognition of non-traditional symptoms may improve patient satisfaction, preempt costly evaluation and misdiagnosis, and lead to further treatment options.
INTRODUCTION: Hypophosphatasia (HPP) is an inborn error of metabolism due to deficiency of tissue non-specific alkaline phosphatase (TNSALP). It is traditionally characterized by rickets in children and osteomalacia in adults, along with fractures, tooth loss, and muscle pain. Neurological symptoms and mental health diagnoses have not been widely reported, and we therefore report their prevalence in a cohort of patients with HPP.
METHODS: A retrospective chart review was performed on a series of 82 HPP patients. Patient charts were reviewed to identify the possible presence and onset of 13 common neurological symptoms.
RESULTS: Median age was 36 years (2 to 79). Seventeen had adult onset HPP (> 18 years) and 65 had pediatric onset HPP (< 18 years). Median time from symptom onset to HPP diagnosis was 8 years (0 to 67). Seventy-four percent had a family history of bone disease, while 17% had a family history of neurologic disease. Bone problems occurred in 89%, dental problems in 77%, and muscle problems in 66%. Fatigue occurred in 66%, headache in 61%, sleep disturbance in 51%, gait change in 44%, vertigo in 43%, depression in 39%, anxiety in 35%, neuropathy in 35%, and hearing loss in 33%.
CONCLUSIONS: The extra-skeletal manifestations of HPP, specifically neurological symptoms, have not been previously well documented. However, mental health diagnoses and neurological symptoms such as headache and sleep disturbance occur commonly in patients with HPP. The recognition of non-traditional symptoms in HPP may improve patient satisfaction, preempt costly evaluation and misdiagnosis, and may lead to further treatment options.

Entities:  

Keywords:  Alkaline phosphatase; Hypophosphatasia; Neurological symptoms; PLP; TNSALP; Vitamin B6

Mesh:

Substances:

Year:  2018        PMID: 30215116     DOI: 10.1007/s00198-018-4691-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  10 in total

1.  Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study.

Authors:  Nicola Hepp; Anja Lisbeth Frederiksen; Morten Duno; Niklas Rye Jørgensen; Jens-Erik Beck Jensen
Journal:  Osteoporos Int       Date:  2022-08-19       Impact factor: 5.071

2.  Characterization of Genetic Variants of Uncertain Significance for the ALPL Gene in Patients With Adult Hypophosphatasia.

Authors:  Raquel Sanabria-de la Torre; Luis Martínez-Heredia; Sheila González-Salvatierra; Francisco Andújar-Vera; Iván Iglesias-Baena; Juan Miguel Villa-Suárez; Victoria Contreras-Bolívar; Mario Corbacho-Soto; Gonzalo Martínez-Navajas; Pedro J Real; Cristina García-Fontana; Manuel Muñoz-Torres; Beatriz García-Fontana
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

3.  Impact of pediatric hypophosphatasia on behavioral health and quality of life.

Authors:  Elizabeth I Pierpont; Jill H Simmons; Katherine J Spurlock; Ryan Shanley; Kyriakie M Sarafoglou
Journal:  Orphanet J Rare Dis       Date:  2021-02-12       Impact factor: 4.123

Review 4.  Tissue-Nonspecific Alkaline Phosphatase-A Gatekeeper of Physiological Conditions in Health and a Modulator of Biological Environments in Disease.

Authors:  Daniel Liedtke; Christine Hofmann; Franz Jakob; Eva Klopocki; Stephanie Graser
Journal:  Biomolecules       Date:  2020-12-08

Review 5.  Hypophosphatasia: A Unique Disorder of Bone Mineralization.

Authors:  Juan Miguel Villa-Suárez; Cristina García-Fontana; Francisco Andújar-Vera; Sheila González-Salvatierra; Tomás de Haro-Muñoz; Victoria Contreras-Bolívar; Beatriz García-Fontana; Manuel Muñoz-Torres
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 6.  Hypophosphatasia.

Authors:  Symeon Tournis; Maria P Yavropoulou; Stergios A Polyzos; Artemis Doulgeraki
Journal:  J Clin Med       Date:  2021-12-01       Impact factor: 4.241

7.  Hearing impairment improved after treatment with asfotase alfa in a case of perinatal hypophosphatasia.

Authors:  Rie Chida-Naomiya; Masaru Shimura; Ryuhei Nagao; Atsushi Kumada; Hisashi Kawashima
Journal:  Mol Genet Metab Rep       Date:  2020-06-06

8.  Investigation of alpl expression and Tnap-activity in zebrafish implies conserved functions during skeletal and neuronal development.

Authors:  Barbara Ohlebusch; Angela Borst; Daniel Liedtke; Stephanie Graser; Tina Frankenbach; Eva Klopocki; Franz Jakob
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

9.  Genotype-Phenotype Associations in 72 Adults with Suspected ALPL-Associated Hypophosphatasia.

Authors:  Nico Maximilian Jandl; Tobias Schmidt; Tim Rolvien; Julian Stürznickel; Konstantin Chrysostomou; Emil von Vopelius; Alexander E Volk; Thorsten Schinke; Christian Kubisch; Michael Amling; Florian Barvencik
Journal:  Calcif Tissue Int       Date:  2020-11-15       Impact factor: 4.333

10.  Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia.

Authors:  Wei-Jian Pan; Rajendra Pradhan; Ryan Pelto; Lothar Seefried
Journal:  J Clin Pharmacol       Date:  2021-06-19       Impact factor: 3.126

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.